Efficacy of Methotrexate versus Azathioprine and Their Steroid Sparing Role in the Treatment of Chronic Actinic Dermatitis: A Randomized Control Trial

Mohammad Majid Paracha, Abdul Qayum khan, F. Sagheer, Hina Zahoor
{"title":"Efficacy of Methotrexate versus Azathioprine and Their Steroid Sparing Role in the Treatment of Chronic Actinic Dermatitis: A Randomized Control Trial","authors":"Mohammad Majid Paracha, Abdul Qayum khan, F. Sagheer, Hina Zahoor","doi":"10.26502/fjhs.047","DOIUrl":null,"url":null,"abstract":"Background Azathioprine is first line immunosuppressive agent in treatment of chronic actinic dermatitis. Steroid sparing role of methotrexate has been effective in different dermatosis and it seems reasonable to use it in the treatment of chronic actinic dermatitis. Methods Patients with chronic actinic dermatitis were randomized to receive methotrexate and systemic steroids in group A and azathioprine and systemic steroids in group B. Tapering of systemic steroids was started at 4 weeks. The response to treatment, exacerbation of disease and side effects of medications were assessed at 4, 8 and 16 weeks follow-up by calculating percentage PASI reduction. Result Among 168 patients, 35(38.09%) patients in group A and 37(44%) patients in group B showed efficacy to the treatment at 4 weeks. On follow-up at 16 weeks, exacerbation of skin lesions was observed in total of 14 (19.44%) patients on tapering of systemic steroids among 72 (42.9%) patients previously showing efficacy to the combination therapy, with 9(24.71%) patients in group A and 5(13.51%) patients in group B.","PeriodicalId":73052,"journal":{"name":"Fortune journal of health sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fortune journal of health sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/fjhs.047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background Azathioprine is first line immunosuppressive agent in treatment of chronic actinic dermatitis. Steroid sparing role of methotrexate has been effective in different dermatosis and it seems reasonable to use it in the treatment of chronic actinic dermatitis. Methods Patients with chronic actinic dermatitis were randomized to receive methotrexate and systemic steroids in group A and azathioprine and systemic steroids in group B. Tapering of systemic steroids was started at 4 weeks. The response to treatment, exacerbation of disease and side effects of medications were assessed at 4, 8 and 16 weeks follow-up by calculating percentage PASI reduction. Result Among 168 patients, 35(38.09%) patients in group A and 37(44%) patients in group B showed efficacy to the treatment at 4 weeks. On follow-up at 16 weeks, exacerbation of skin lesions was observed in total of 14 (19.44%) patients on tapering of systemic steroids among 72 (42.9%) patients previously showing efficacy to the combination therapy, with 9(24.71%) patients in group A and 5(13.51%) patients in group B.
甲氨蝶呤与硫唑嘌呤的疗效及其类固醇保留作用治疗慢性光化性皮炎:一项随机对照试验
背景硫唑嘌呤是治疗慢性光化性皮炎的一线免疫抑制剂。甲氨蝶呤的类固醇保留作用在不同的皮肤病中都是有效的,在慢性光化性皮炎的治疗中似乎是合理的。方法慢性光化性皮炎患者随机分为甲氨蝶呤和全身类固醇治疗组,硫唑嘌呤和全身类固醇治疗组,4周开始逐渐减少全身类固醇治疗。通过计算PASI减少百分比,在随访4、8和16周时评估治疗反应、疾病恶化和药物副作用。结果168例患者中,A组35例(38.09%),B组37例(44%),治疗4周有效。在16周的随访中,在72例(42.9%)先前对联合治疗有效的患者中,共有14例(19.44%)患者在全体性类固醇减量治疗后皮肤病变加重,其中A组9例(24.71%),B组5例(13.51%)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信